Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 05, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The filing details a specific transaction on August 30, 2006, where the Administrators of the SmithKline Beecham Employee Benefit Trust sold 12,272 Ordinary shares on behalf of participants in the GlaxoSmithKline Bonus Investment Plan. The shares were sold at a price of GBP 14.82 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(b). The Trust is identified as a discretionary fund for non-US employees and former employees, with Director Mr. J S Heslop noted as having an interest in the fund similar to other beneficiaries.
Key Facts for Investor Verification
- Transaction Date: August 30, 2006.
- Shares Sold: 12,272 Ordinary shares.
- Transaction Price: GBP 14.82 per share.
- Entity Involved: SmithKline Beecham Employee Benefit Trust (acting for Bonus Investment Plan participants).
- Director Interest: Mr. J S Heslop is noted as interested in the fund's holdings.